| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director | Director, 10% Owner
10 companies
Ecor1 Capital, LLC is a 10% Owner at ADAPY with holdings across 10 companies. Recent SEC Form 4 filings include 15 buys and 2 sells.
Estimated insider holdings value: $1503.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2022 | ANAB Anaptysbio, Inc | 10% Owner | Buy | 668,237 | $21.63 | $14,453,966.31 | +9.8% | -2.9% | +1.2% | |
| Jan 12, 2022 | PRTA Prothena Corp Public Ltd Co | 10% Owner | Buy | 300,000 | $37.50 | $11,250,300.00 | +2.7% | -5.5% | +53.5% | |
| Oct 1, 2021 | CRVS Corvus Pharmaceuticals, Inc. | 10% Owner | Sell | 5,000,000 | $5.01 | $25,059,900.00 | -69.8% | -48.9% | -83.0% | |
| May 4, 2021 | ANAB Anaptysbio, Inc | Director, 10% Owner | Buy | 221,500 | $23.24 | $5,147,443.53 | +1.0% | +0.0% | +3.5% | |
| Apr 27, 2021 | ANAB Anaptysbio, Inc | Director, 10% Owner | Buy | 147,300 | $23.63 | $3,480,233.08 | +0.7% | +0.8% | -5.9% | |
| Mar 24, 2021 | PRTA Prothena Corp Public Ltd Co | 10% Owner | Buy | 875,000 | $20.75 | $18,156,250.00 | +8.6% | +78.5% | +48.9% | |
| Mar 9, 2021 | ANAB Anaptysbio, Inc | 10% Owner | Buy | 3,308,800 | $18.93 | $62,622,736.04 | +31.6% | +24.8% | +62.9% | |
| Feb 24, 2021 | PRTA Prothena Corp Public Ltd Co | 10% Owner | Buy | 55,200 | $21.24 | $1,172,384.64 | +0.3% | - | - | |
| Feb 23, 2021 | ANAB Anaptysbio, Inc | 10% Owner | Buy | 29,500 | $25.48 | $751,657.05 | +0.8% | -7.6% | +12.1% | |
| Feb 18, 2021 | PRTA Prothena Corp Public Ltd Co | 10% Owner | Buy | 44,100 | $3.68 | $162,102.78 | +0.4% | - | - |